Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERIDONE vs ARISTADA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Schizophrenia,Bipolar I disorder (acute manic or mixed episodes),Irritability associated with autistic disorder,Adjunctive therapy in major depressive disorder,Tourette syndrome (off-label),Obsessive-compulsive disorder (off-label)
Schizophrenia,Maintenance monotherapy of bipolar I disorder in adults
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Extensively metabolized in the liver via CYP2D6 and CYP3A4 to 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The parent drug and metabolite are equally active.
Aripiprazole lauroxil is hydrolyzed by esterases to N-hydroxymethyl aripiprazole, which is then converted to aripiprazole. Aripiprazole is primarily metabolized by CYP2D6 and CYP3A4.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Risperidone: 90% bound to albumin and alpha-1-acid glycoprotein; 9-hydroxyrisperidone: 77% bound
>99% bound, primarily to albumin.
Risperidone: 1-2 L/kg; 9-hydroxyrisperidone: 0.5-1 L/kg; extensive tissue distribution
Approximately 4.9 L/kg (based on aripiprazole), indicating extensive tissue distribution.
Oral: 70% (tablet), 70% (oral solution); intramuscular: 100% for immediate-release, 28% for long-acting injection relative to oral
Intramuscular: 100% (complete release from injection site). Oral aripiprazole: 87%.
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: initiate at 0.5 mg orally twice daily for at least 1 week, then increase by 0.5 mg twice daily as tolerated; maximum 3 mg/day.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Child-Pugh Class A or B: initiate at 0.5 mg orally twice daily, increase cautiously. Class C: avoid or use with extreme caution; no specific established dose.
No dosage adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of studies.
Adolescents (13-17 yr) with schizophrenia: initial 0.5 mg orally once daily, titrate to 3 mg/day as tolerated. Children (10-17 yr) with bipolar mania: initial 0.5 mg once daily, titrate to 1-2.5 mg/day. Weight-based not standard; use fixed dosing.
Safety and efficacy not established in pediatric patients under 18 years of age.
Initiate at 0.5 mg orally once daily; increase by 0.5 mg/day increments; target dose 1-2 mg/day; monitor for orthostasis and extrapyramidal symptoms.
No specific dosage adjustment recommended, but caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects and consider lower initial doses if clinically appropriate.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (stroke, TIA) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,QT interval prolongation,Priapism,Dysphagia,Body temperature dysregulation,Potential for cognitive and motor impairment
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events in elderly patients with dementia,Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension,Leukopenia, neutropenia, and agranulocytosis,Seizures,Body temperature dysregulation,Dysphagia,Potential for cognitive and motor impairment
Hypersensitivity to risperidone or any component of the formulation
Hypersensitivity to aripiprazole or any component of the formulation
Avoid grapefruit and grapefruit juice; may increase risperidone plasma concentrations. Alcohol can potentiate CNS depression and increase risk of side effects. No specific food restrictions; take with or without food. High-fat meals may slightly increase absorption.
Avoid grapefruit juice due to CYP3A4 inhibition. No specific food restrictions beyond that.
Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposure may cause neonatal extrapyramidal symptoms (e.g., agitation, hypertonia, tremors) and withdrawal symptoms (e.g., respiratory distress, feeding difficulties).
Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripiprazole caused developmental toxicity, including teratogenic effects, at doses similar to or less than the maximum recommended human dose (MRHD). During the first trimester, there is a potential risk of major congenital malformations, although data are limited. During the second and third trimesters, exposure may increase the risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.
Risperidone is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5 for the parent drug and 0.3 for the active moiety (risperidone + 9-hydroxyrisperidone). Relative infant dose (RID) is about 2-4% of the maternal weight-adjusted dose. Monitor the infant for sedation, poor feeding, and extrapyramidal effects. The benefit of breastfeeding should be weighed against potential risks.
Aripiprazole is excreted in human breast milk; the milk-to-plasma ratio (M/P) is approximately 0.5 to 3.0 based on limited data. In lactating women, the relative infant dose (RID) is estimated to be about 1.4% to 8.3% of the weight-adjusted maternal dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for Aristada and any potential adverse effects on the breastfed child. Monitor the infant for signs of sedation, extrapyramidal symptoms, or inadequate weight gain.
Increased clearance of risperidone in pregnancy may require dose adjustments. Some studies suggest a dose increase of 20-30% during the second and third trimesters to maintain therapeutic levels. TDM is recommended to guide dosing, with target trough concentrations similar to non-pregnant patients (10-20 ng/m L for the active moiety). Postpartum dose should be reduced to pre-pregnancy levels.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) may reduce aripiprazole levels. Although no specific dose adjustment guidelines are established for Aristada, therapeutic drug monitoring of aripiprazole and its active metabolite dehydroaripiprazole may be considered to maintain efficacy. Dose adjustments should be individualized based on clinical response and tolerability, with careful monitoring during pregnancy and postpartum.
Monitor for orthostatic hypotension, especially during dose titration. Risperidone can cause QTc prolongation; obtain baseline ECG in at-risk patients. Extrapyramidal symptoms (EPS) are dose-dependent; use lowest effective dose. In elderly dementia patients, increased risk of cerebrovascular events; not approved for this indication. Prolactin elevation is common; monitor for gynecomastia, galactorrhea, and sexual dysfunction. Taper slowly to avoid withdrawal dyskinesia.
Initiate with a single 672 mg test dose to confirm tolerability. Administer only via gluteal IM injection; do not administer IV. The drug forms a liquid crystal depot upon injection. Ensure proper needle selection: 2-inch needle for gluteal injection. Do not massage injection site. Monitor for post-injection syndrome (rare but serious).
Take risperidone exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol and grapefruit juice as they may affect drug levels and increase side effects.,Rise slowly from sitting or lying down to prevent dizziness from low blood pressure.,Report any involuntary muscle movements, restlessness, or stiffness to your healthcare provider.,Notify your doctor if you experience breast swelling, discharge, or sexual problems.,Do not drive or operate heavy machinery until you know how risperidone affects you.
Do not stop taking this medication abruptly; continue regular visits for injections.,Report any severe muscle stiffness, fever, confusion, or irregular heartbeat immediately.,Avoid alcohol and grapefruit juice while on this medication.,You may experience injection site reactions; notify your doctor if they worsen.,Use effective contraception if of childbearing potential; discuss risks with your doctor.
"Carvedilol, a nonselective beta-blocker with alpha1-blocking activity, may enhance the hypotensive effects of risperidone, an atypical antipsychotic with alpha1-adrenergic antagonism. This additive pharmacodynamic interaction can lead to exaggerated blood pressure reduction, orthostatic hypotension, dizziness, and increased risk of syncope, particularly during initial dosing or dose titration. Patients with cardiovascular comorbidity or volume depletion are at heightened risk for adverse outcomes such as falls or cardiac ischemia."
"Cilazapril, an angiotensin-converting enzyme inhibitor (ACEI), reduces angiotensin II production and aldosterone secretion, leading to vasodilation and decreased blood pressure. Risperidone, an atypical antipsychotic, can cause orthostatic hypotension through alpha-1 adrenergic receptor blockade. Concurrent use may result in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope, particularly at treatment initiation or dose adjustments."
"Coadministration of risperidone and pizotifen may lead to additive anticholinergic and sedative effects due to their overlapping pharmacological profiles. Risperidone, an atypical antipsychotic with histamine H1 receptor antagonist properties, combined with pizotifen, a serotonin antagonist with strong anticholinergic and antihistaminergic activity, can result in excessive sedation, cognitive impairment, and peripheral anticholinergic effects such as dry mouth, constipation, and urinary retention. Clinically, this interaction increases the risk of falls, confusion, and reduced functional status, especially in elderly patients or those with pre-existing central nervous system depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERIDONE vs ARISTADA, answered by our medical review team.
RISPERIDONE is a Atypical Antipsychotic that works by Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.. ARISTADA is a Atypical Antipsychotic that works by Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERIDONE and ARISTADA depend on the specific clinical indication. These are both Atypical Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERIDONE is: Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.. The standard adult dose of ARISTADA is: Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERIDONE and ARISTADA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERIDONE is classified as Category A/B. Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposu. ARISTADA is classified as Category C. Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripipr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.